We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Orserdu A Menarini Australia Pty Ltd
Product name
Orserdu
Sponsor
Accepted date
Feb-2024
Active ingredients
elacestrant dihydrochloride
Proposed indication
Indicated for the treatment of postmenopausal patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Application type
A (new medicine)
Publication date
Feb-2024